DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses
dc.contributor.author | Li, Haiying | |
dc.contributor.author | Wang, Shixia | |
dc.contributor.author | Hu, Guangnan | |
dc.contributor.author | Zhang, Lu | |
dc.contributor.author | Liu, Shuying | |
dc.contributor.author | Lu, Shan | |
dc.date.accessioned | 2023-04-12T12:44:56Z | |
dc.date.available | 2023-04-12T12:44:56Z | |
dc.date.issued | 2021-04-14 | |
dc.identifier.citation | Li H, Wang S, Hu G, Zhang L, Liu S, Lu S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg Microbes Infect. 2021 Dec;10(1):833-841. doi: 10.1080/22221751.2021.1918026. PMID: 33853515; PMCID: PMC8812797. | en_US |
dc.identifier.eissn | 2222-1751 | |
dc.identifier.doi | 10.1080/22221751.2021.1918026 | en_US |
dc.identifier.pmid | 33853515 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/51940 | |
dc.description.abstract | While DNA prime-protein boost vaccination approach has been widely used in preclinical and clinical studies especially in the field of HIV vaccine development, the exact role of DNA immunization has not been fully identified. Our previous work demonstrated that DNA immunization was able to elicit T follicular helper (Tfh) cell responses and germinal center (GC) B cell development in a mouse model. In the current report, a mouse immunogenicity study was conducted to further ask whether DNA immunization is able to elicit antigen-specific B cell responses. Using HIV-1 Env as model antigen delivered in the form of DNA prime-protein boost, our data demonstrated that DNA prime was able to enhance the antigen-specific B cell responses for both Env-specific antibody secreting cells (ASC) and memory B cells. Furthermore, the DNA priming can greatly reduce the need of including an adjuvant as part of the recombinant protein vaccine boost formulation. Our findings revealed one mechanism that supports the value of DNA priming in assisting the inductin of high affinity and long lasting antigen specific antibody responses. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Emerging Microbes & Infections | en_US |
dc.relation.url | https://doi.org/10.1080/22221751.2021.1918026 | en_US |
dc.rights | © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrest- ricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | B cell | en_US |
dc.subject | DNA vaccine | en_US |
dc.subject | HIV-1 | en_US |
dc.subject | antibody | en_US |
dc.subject | envelope glycoprotein | en_US |
dc.subject | heterologous prime – boost | en_US |
dc.subject | protein vaccine | en_US |
dc.title | DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses | en_US |
dc.type | Journal Article | en_US |
dc.source.journaltitle | Emerging microbes & infections | |
dc.source.volume | 10 | |
dc.source.issue | 1 | |
dc.source.beginpage | 833 | |
dc.source.endpage | 841 | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.source.country | United States | |
dc.identifier.journal | Emerging microbes & infections | |
refterms.dateFOA | 2023-04-12T12:44:57Z | |
dc.contributor.department | Medicine | en_US |